@
β²G
@
5) Ohtani, T., K. Ishihara, T. Atsumi, Y. Yoshida, K. Nishida, M. Narimatsu, T. Shirogane, M. Hibi and T. Hirano. gp130-mediated signalings as therapeutic targets. Emerging Therapeutic Targets,4, 459-479, 2000.
4) Shirogane, T., T. Fukada, J.M.M. Muller, D. T. Shima, M. Hibi, and T. Hirano, Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and anti-apoptosis. Immunity 11, 709-719, 1999. (PubMed) (Full Text in Immunity)
3) Fukada, T., Y. Yoshida, K. Nishida, T. Ohtani, T. Shirogane, M. Hibi, and T. Hirano. Signaling through gp130: Toward a general scenario of cytokine action. Growth Factors 17, 81-91, 1999. (PubMed)
2) Nishida, K., Y. Yoshida, M. Itoh, T. Fukada, T. Ohtani, T. Shirogane, T. Atsumi, M. Takahashi-Tezuka, K. Ishihara, M. Hibi, and T. Hirano. Gab-family adapter proteins act downstream of cytokine and growth factor receptors, and T and B cell antigen receptors. Blood, 93:1809-1816, 1999.(PubMed)
1) Fukada, T., T. Ohtani, Y. Yoshida, T. Shirogane, K. Nishida, K. Nakajima, M. Hibi, and T. Hirano. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell cycle transition. EMBO J. 17: 6670-6677,1998 (Abstract)(PubMed) (Full Text in EMBO J).